How many drugs treat Carcinoma of thyroid?

Drug Landscape tracks 5 marketed treatments for Carcinoma of thyroid (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/carcinoma-of-thyroid.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Carcinoma of thyroid — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Carcinoma of thyroid (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Carcinoma of thyroid, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Caprelsa	VANDETANIB	Sanofi	Kinase Inhibitor [EPC]	Receptor-interacting serine/threonine-protein kinase 2	2011-01-01
Nexavar	SORAFENIB	Bayer	Kinase Inhibitor [EPC]	Vascular endothelial growth factor receptor 2	2005-01-01
Caprelsa	Caprelsa	Genzyme, a Sanofi Company		AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial
Nexavar	Nexavar	Fujian Medical University		Citron Rho-interacting kinase, Cyclin-dependent kinase-like 2, Cyclin-dependent kinase-like 3
Zactima	Zactima	Barbara Ann Karmanos Cancer Institute		AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Barbara Ann Karmanos Cancer Institute · 1 drug in Carcinoma of thyroid
Bayer · 1 drug in Carcinoma of thyroid
Fujian Medical University · 1 drug in Carcinoma of thyroid
Genzyme, a Sanofi Company · 1 drug in Carcinoma of thyroid
Sanofi · 1 drug in Carcinoma of thyroid

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Carcinoma of thyroid:

Cite this brief

Drug Landscape (2026). Carcinoma of thyroid — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/carcinoma-of-thyroid. Accessed 2026-06-10.

Carcinoma of thyroid full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing